Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA Turns Down Sensor-Embedded Tablet For Monitoring Medication Adherence

Executive Summary

The agency says it needs more information, and especially more usability testing, before it can approve a new drug application on a combination product that integrates Otsuka’s Abilify antipsychotic with an ingestible sensor made by Proteus, intended to improve medication adherence.

Advertisement

Related Content

FDA Guidance Sheds Light On Human Factor Studies For Combo Products

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register